Send to:

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2013 Mar 1;19(5):958-60. doi: 10.1158/1078-0432.CCR-12-3586. Epub 2013 Jan 22.

Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy?

Author information

  • 1Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.


EGF receptor (EGFR)-specific monoclonal antibodies (mAb) display limited therapeutic efficacy in EGFR-positive solid tumors. To overcome this limitation, the significant improvement of the antibody-dependent cell-mediated cytotoxicity-mediated antitumor activity of a novel EGFR-specific mAb is described. Its potential impact on the efficacy of immunotherapy for EGFR-positive solid tumors is discussed.

©2013 AACR.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk